未登录 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
Clinically important improvements in 6-min walk distance (6MWD) and forced vital capacity (FVC) in adults with late- onset Pompe disease (LOPD) switching from alglucosidase alfa (alg) to cipaglucosidase alfa plus miglustat (cipa plus mig) in the PROPEL study Schoser, Benedikt; Kushlaf, Hani; Wenninger, Stephan; Hummel, Noemi; Clarke, Sophie; Crabtree, Matthew; Fox, Brian; Gloeckner, Birgit; Holdbrook, Fred; Jain, Vipul; Peceny, Markus; Claeys, Kristl G. 分享 收藏
分享 收藏
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials Silverberg, Jonathan, I; Wollenberg, Andreas; Reich, Adam; Thaci, Diamant; Legat, Franz J.; Papp, Kim A.; Gold, Linda Stein; Bouaziz, Jean-David; Pink, Andrew E.; Carrascosa, Jose Manuel; Rewerska, Barbara; Szepietowski, Jacek C.; Krasowska, Dorota; Havlickova, Blanka; Kalowska, Monika; Magnolo, Nina; Pauser, Sylvia; Nami, Navid; Sauder, Maxwell B.; Jain, Vipul; Padlewska, Kamila; Cheong, Soo Yeon; Morel, Patricia Fleuranceau; Ulianov, Liliana; Piketty, Christophe 分享 收藏
分享 收藏
分享 收藏
Baseline demographics of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in enzyme replacement therapy-experienced adults with late-onset Pompe disease Roberts, Mark E.; Cole, Duncan; Deegan, Patrick B.; Geberhiwot, Tarekegn; Hughes, Derralynn; Lachmann, Robin; Sharma, Reena; Jain, Vipul; Moffat, Elizabeth; Rutecki, Jasmine; Clarke, Sophie 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria Remibrutinib是一种新型的BTK抑制剂,在慢性自发性荨麻疹中表现出良好的疗效和安全性 Maurer, Marcus; Berger, William; Gimenez-Arnau, Ana; Hayama, Koremasa; Jain, Vipul; Reich, Adam; Haemmerle, Sibylle; Lheritier, Karine; Walsh, Pauline; Xia, Summer; Storim, Julian 分享 收藏